Artificial intelligence platform for molecular targeted therapy : (Record no. 49738)

MARC details
000 -LEADER
fixed length control field 04318nam a2200433 i 4500
003 - CONTROL NUMBER IDENTIFIER
control field WSP
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20260416153409.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 210408s2021 si ob 001 0 eng
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9789811232312
-- (ebook)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Cancelled/invalid ISBN 9789811232305
-- (hardback)
072 #7 - SUBJECT CATEGORY CODE
Subject category code SCI
Subject category code subdivision 010000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code TEC
Subject category code subdivision 059000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code COM
Subject category code subdivision 004000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 615.1/9
Edition number 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Fernández, Ariel,
245 10 - TITLE STATEMENT
Title Artificial intelligence platform for molecular targeted therapy :
Remainder of title a translational science approach /
Statement of responsibility, etc by Ariel Fernández, Daruma Institute, Argentina & AF Innovation, USA & CONICET-National Research Council, Argentina.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (xviii, 450 pages)
505 0# - FORMATTED CONTENTS NOTE
Contents Foreword -- About the author -- Preface -- Propaedeutic to artificial intelligence -- Epistructural biology : a conceptual and representational framework for AI-based drug design -- Artificial intelligence constructs in vivo reality to expedite protein folding -- Epistructural meta-analysis of functional genomics repositories: Towards an ai platform to infer amyloidogenic propensity -- Molecular evolution from the perspective of epistructural biology -- Epistructural biochemistry -- Epistructural drug design : next-generation targeted therapeutics -- Anticancer treatment synergizing targeted therapies with immune responses -- Epistructurally engineered cancer susceptibility to checkpoint immunotherapy and the ai-empowered steering of cancer evolution towards extinction -- AI-empowered molecular dynamics -- Artificial intelligence guides drug design in the absence of information on target structure and regulation and unravels the origin of cooperativity -- Artificial intelligence teaches drugs to target proteins by solving the drug-induced folding problem -- Epilogue : AI constructs its own physics -- Appendix 1 : code for dehydron identification -- Index.
520 ## - SUMMARY, ETC.
Summary, etc "In the era of big biomedical data, there are many ways in which artificial intelligence (AI) is likely to broaden the technological base of the pharmaceutical industry. Cheminformatic applications of AI involving the parsing of chemical space are already being implemented to infer compound properties and activity. By contrast, dynamic aspects of the design of drug/target interfaces have received little attention due to the inherent difficulties in dealing with physical phenomena that often do not conform to simplifying views. This book focuses precisely on dynamic drug/target interfaces and argues that the true game change in pharmaceutical discovery will come as AI is enabled to solve core problems in molecular biophysics that are intimately related to rational drug design and drug discovery. Here are a few examples to convey the flavor of our quest: How do we therapeutically impair a dysfunctional protein with unknown structure or regulation but known to be a culprit of disease? In regards to SARS-CoV-2, what is the structural impact of a dominant mutation?, how does the structure change translate into a fitness advantage?, what new therapeutic opportunity arises? How do we extend molecular dynamics simulations to realistic timescales, to capture the rare events associated with drug targeting in vivo? How do we control specificity in drug design to selectively remove side effects? This is the type of problems, directly related to the understanding of drug/target interfaces, that the book squarely addresses by leveraging a comprehensive AI-empowered approach"--Publisher's website.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drugs
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drug development.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Artificial intelligence.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Molecular dynamics.
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://www.worldscientific.com/worldscibooks/10.1142/12160#t=toc">https://www.worldscientific.com/worldscibooks/10.1142/12160#t=toc</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Electronic Books
100 1# - MAIN ENTRY--PERSONAL NAME
Dates associated with a name 1957-
Relator term author.
264 #1 -
-- Singapore :
-- World Scientific,
-- 2021.
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
538 ## - SYSTEM DETAILS NOTE
System details note Mode of access: World Wide Web.
538 ## - SYSTEM DETAILS NOTE
System details note System requirements: Adobe Acrobat Reader.
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc Includes bibliographical references and index.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
General subdivision Design.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
9 (RLIN) 4
655 #0 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Electronic books.
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Location Date of Cataloging Total Checkouts Full call number Barcode Date last seen Uniform Resource Identifier Price effective from Koha item type
    Dewey Decimal Classification     CUTN Central Library CUTN Central Library 16/04/2026   615.1/9 EB04934 16/04/2026 https://doi.org/10.1142/12160 16/04/2026 Electronic Books